These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1103 related articles for article (PubMed ID: 27460757)

  • 1. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
    Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
    J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving immunotherapy strategies in urothelial cancer.
    Brancato SJ; Lewi K; Agarwal PK
    Am Soc Clin Oncol Educ Book; 2015; ():e284-90. PubMed ID: 25993187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.
    Gupta M; Kates M; Bivalacqua TJ
    Curr Opin Oncol; 2019 May; 31(3):183-187. PubMed ID: 30893148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
    Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
    Todenhöfer T; Boegemann M
    Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of immunotherapy in urological cancers.
    Bosnali E; Akdas EM; Telli E; Teke K; Kara O
    Arch Ital Urol Androl; 2024 May; 96(2):12307. PubMed ID: 38818794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
    Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
    Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
    Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
    J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer.
    Lobo N; Martini A; Kamat AM
    Expert Rev Anticancer Ther; 2022 Apr; 22(4):361-370. PubMed ID: 35212590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
    García-Perdomo HA; Sánchez AL; Spiess PE
    Urol Oncol; 2022 Sep; 40(9):409.e1-409.e8. PubMed ID: 35232680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.